SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The 401jk (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and also the 401k. The 401k total holdings are valued at around $12 trillion USD and it is the most popular retirement savings plan in the US. As time passes forevermore true retirement, or as we like to call it real freedom will only become much harder and harder for people to attain.  Through meme fueled laser focus and cyperphunk ideology the 401jK meme retirement fund token and community aim to point out the absurdities of how rigged our current system is, and how only insiders and those with power are starting the benefit from the increased centralization of cryptocurrency.........while also aiming to flip the $12 trillion USD 401k system to achieve freedom before our backs and knees are breaking.

401jK

$401JK is trending as community members rally around its anti-establishment narrative, viewing it as a movement against traditional retirement systems. Buoyed by a strong and active community, the coin's mission is to challenge the status quo. Discussions revolve around its potential for significant growth and staking opportunities.

Alchemy Pay

ACH is trending with community members discussing its potential and expressing frustration over its price action. Some point to upcoming catalysts like new partnerships and the potential launch of Alchemy Chain. Others speculate on buyout or merger possibilities, while many are focused on short-term price movements and potential gains.

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

eXoZymes Inc.

eXoZymes ($EXOZ) is trending due to its advancements in cell-free biomanufacturing, particularly the 100-fold scale-up of NCT production with impressive efficiency. The community is focused on the potential of NCT in the nutraceutical and pharmaceutical markets, especially its role alongside GLP-1 drugs and in addressing liver health. Discussions also highlight the company's AI-driven approach and partnerships, positioning eXoZymes as a leader in sustainable biomanufacturing.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca ($ORCA) is trending due to an explosive price surge following a $36M Upbit exchange hack, which triggered a short squeeze as traders aggressively shorted the token. Community members are actively discussing entry points and potential short-term gains, while also pointing to the project's ecosystem growth and accessibility improvements as bullish catalysts. Recent ecosystem developments like MetaMask integration and potential buybacks may be contributing to positive sentiment.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community anticipates a breakout, referencing bullish chart patterns and a potential surge towards $110. Discussions include long-term potential, historical price comparisons, and its role as 'digital silver' in the crypto market, while some traders express frustration with recent price action and volatility.

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

Ligand Pharmaceuticals ($LGND) is trending due to recent analyst target price raises and positive ratings, highlighting an improved growth outlook. Community discussion points to potential pipeline valuation debates and upcoming catalysts, including key PDUFA dates and trial data releases. The stock's royalty-based business model and diversified biopharma strategy are also attracting attention.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

DESTINY TECH 100 INC is trending due to speculation surrounding a potential SpaceX IPO and DXYZ's significant holdings in the company, driving investor interest. The community is actively debating the fund's valuation relative to its net asset value and comparing it to other SpaceX investment options like EchoStar. Discussions also include DXYZ's other private tech holdings, such as OpenAI, and their potential impact on the stock's price.

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard is trending due to news around stablecoins and blockchain, with community members weighing the potential disruption to traditional payment networks. Some analysts highlight the company's proactive approach and investments in these areas, while others suggest the stock may be oversold. Bullish community members see any dip as a buying opportunity, citing Mastercard's strong fundamentals and historical performance.

Sui is an innovative layer-1 blockchain platform crafted to meet the demands of global adoption, providing a secure, robust, and scalable development environment. Rooted in a unique object-centric data model and fortified by the trusted Move programming language, Sui is engineered to tackle the inefficiencies found in current blockchain frameworks.  In addition to its solid technical underpinnings, Sui places a strong emphasis on user experience, aiming to remove common barriers encountered in blockchain interactions. Through groundbreaking features such as zkLogin, sponsored transactions, and programmable transaction blocks, Sui sets a new standard for user accessibility and friendliness within Web3 applications.  Unique elements of Sui Sui’s innovative architecture ensures swift transactions with stable fees and high throughput through horizontal scaling. Its object-oriented design offers deep composability for developers, enabling tailored object types with network-wide compatibility. This revolutionizes asset and protocol collaboration, fostering product innovation.  The platform's object-oriented approach dramatically improves transaction processing, enabling parallel execution and faster completion times. Additionally, unique consensus requirements expedite transaction finalization while maintaining stability. Sui prioritizes overcoming Web3 adoption barriers, offering native tools like zkLogin and sponsored transactions for wallet onboarding and fee management.  Move integration into Sui's data model combines innovation with security, mitigating common exploits found in smart contract languages. This empowers developers and users with a secure and intuitive platform, accelerating the evolution of Web3 applications.  About the Sui token The SUI token serves four primary functions within the Sui ecosystem: Proof-of-stake participation - Sui implements a delegated proof-of-stake mechanism, rewarding honest behavior by validators and SUI token holders who stake with them. Gas fee payments - SUI tokens cover gas fees for executing transactions and storing data onchain. Application utility - SUI is a versatile asset, integral to various applications within Sui’s ecosystem, including decentralized exchanges, lending platforms, gaming, and more. Governance - The SUI token empowers holders to participate in on-chain voting on significant matters like protocol upgrades and platform changes, shaping the future of Sui.  Additionally, the Sui storage fund ensures fair compensation for validators by distributing stake rewards over time and covering storage costs for previously stored on-chain data. This tokenomic strategy promotes indefinite data storage while maintaining fair compensation for validators, fostering long-term sustainability.

SUI is trending as the community discusses its potential for institutional adoption and its underlying technology, including the Move language. Comparisons are being drawn to other Layer 1 solutions like Keeta, with community members debating the merits of each. Catalysts mentioned include potential ETF approvals and increased transaction volume.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is trending as investors discuss the potential approval of Anaphylm, a needle-free epinephrine film, with the PDUFA date approaching at the end of January. Community talking points revolve around comparing Anaphylm to existing treatments like EpiPen and Neffy, as well as speculating on the likelihood of approval and potential buyout scenarios. Some investors are closely monitoring short interest and recent institutional activity for signals about the FDA's decision.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Merus&nbsp;NV’s stock climbed to a record high on Monday after Genmab said it would acquire the company in an $8 billion all-cash transaction, despite a broad wave of analyst downgrades.<a href="https://stocktwits.com/symbol/MRUS">Shares of Merus</a> jumped 36% to close at $93.70 on Monday, before edging up 0.1%, in after-hours trading.Needham analyst Ami Fadia downgraded Merus to ‘Hold’ from ‘Buy’ without a price target after the company entered into the agreement. Citi downgraded the stock to ‘Neutral’ from ‘Buy’ and cut its price target to $97 from $101, saying the possibility of a competing bid is very low.Wells Fargo analyst Eva Fortea Verdejo lowered her rating to ‘Equal Weight’ from ‘Overweight’ and raised the price target to $97 from $95. Canaccord downgraded Merus to ‘Hold’ from ‘Buy’ with a price target of $97, while William Blair cut its rating to ‘Market Perform’ from ‘Outperform’.Truist moved Merus to ‘Hold’ from ‘Buy’ and raised the price target to $97 from $88, saying the deal terms are “favorable, all things considered.”LifeSci Capital analyst Charles Zhu downgraded Merus to ‘Market Perform’ from ‘Outperform’ with a price target of $97. Guggenheim analyst Michael Schmidt downgraded the stock to ‘Neutral’ from ‘Buy’ and cut the target to $97 from $109.H.C. Wainwright downgraded Merus to ‘Neutral’ from ‘Buy’ and reduced its price target to $97 from $135, saying Merus’ full value is priced into the deal.The transaction, unanimously approved by both companies’ boards, gives Genmab full ownership of petosemtamab, Merus’ late-stage antibody therapy for head and neck cancer, which has received two Breakthrough Therapy Designations from the U.S. Food and Drug Administration.On Stocktwits, retail sentiment for Merus was ‘extremely bullish’ amid a 3,800% surge in 24-hour message volume.Some users congratulated Merus shareholders on the buyout, saying the acquisition marked a rewarding moment for long-term investors who held through difficult periods.<stembedurl>https://stocktwits.com/BiotechBonesaw/message/630422083</stembedurl><stembedurl>https://stocktwits.com/Following_the_trend/message/630325826</stembedurl>Another user noted that the deal underscored the potential for other biotech firms to be acquired at higher valuations, citing that Merus was acquired by Genmab for $8 billion, despite its focus on the relatively smaller head and neck cancer market.<stembedurl>https://stocktwits.com/Power2k/message/630394868</stembedurl><a href="https://stocktwits.com/symbol/MRUS">Merus’ stock</a> has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Merus logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Merus Stock Soars To All-Time High As Genmab Announces $8B Takeover — Analysts Turn Cautious, Retail Crowd Cheers The Deal

The $8 billion all-cash deal gives Genmab full ownership of Merus’ late-stage antibody therapy petosemtamab, which has received two FDA Breakthrough Therapy Designations for head and neck cancer.

Equity

Retail chatter around Merus spiked late on Sunday after a report said Denmark’s Genmab is reportedly in advanced talks to acquire the Dutch biotech, which is developing a potential treatment for head and neck cancer.<a href="https://stocktwits.com/symbol/MRUS">Merus’ U.S.-listed stock</a> closed at $68.89 on Friday, up 1.2%, and surged over 19% to $82.03 in overnight trading.Merus has reportedly received multiple takeover offers from large pharmaceutical companies in recent weeks and could announce a deal within days, although there is no certainty that the talks will result in a transaction, Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-28/genmab-is-said-in-talks-to-buy-cancer-drugmaker-merus?srnd=homepage-americas&amp;sref=8QBk7toa">reported</a>, citing people familiar with the matter.If finalized, the deal would be Genmab’s largest acquisition to date, Bloomberg reported. Genmab has a market capitalization of about 118 billion kroner ($18.5 billion), while Merus is valued at around $5.2 billion on the Nasdaq.Merus’ shares have risen sharply since May, when the company said its experimental drug petosemtamab was more effective than the current standard of care in shrinking tumors in head-and-neck cancer patients when combined with Keytruda. Bloomberg Intelligence has forecast that the drug could become a blockbuster therapy and exceed $1 billion in sales by 2030.Merus is also testing petosemtamab in advanced colon cancer, a larger and more lucrative potential market. Its smaller rival, Bicara Therapeutics, is developing a treatment for the same condition but remains further behind in development.On Stocktwits, retail sentiment for Merus was ‘bullish’ amid ‘high’ message volume, placing the stock among the top ten trending equities on the platform. Meanwhile, Genmab drew ‘extremely bearish’ sentiment amid ‘high’ message volume.One user congratulated the company on the reported development, while another user asked about the potential buyout price, reflecting curiosity about the rumored deal’s details.<stembedurl>https://stocktwits.com/CrispDry/message/630278149</stembedurl><stembedurl>https://stocktwits.com/Fugazi_/message/630280727</stembedurl>Merus’ U.S.-listed stock has risen 63.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Merus Buyout Rumor Gets Retail Traders Buzzing — Genmab Said To Be Leading The Race

Merus’ cancer drug petosemtamab, developed for head and neck tumors, has shown stronger results than the current standard of care and is projected to top $1 billion in annual sales by 2030.

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Current Price	$31.31
Prev Close	$32.30
Open	$31.81
Dividend Yield	0.00%
50-Day Moving Average	$30.88
Beta	0.58
Avg. Volume	1.79M
PE Ratio	13.19

52-Week High	$33.65
52-Week Low	$17.24
Market Capitalization	$19.29B
EPS (Annual)	$1.77
Price to Book	3.35
Revenue Per Employee	$1.16M
Enterprise Value/EBITDA	N/A

GMXAY
GENMAB A/S/S ADR

Feed

News

Sentiment

Fundamentals

Info

Latest GMXAY News

GMXAYGENMAB A/S/S ADR